Published on: 2025-05-22 18:35:18
An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease. In clinical trial data published over the weekend, Eli Lilly’s lepodisiran was found to dramatically reduce people’s levels of a dangerous kind of cholesterol called lipoprotein(a), or Lp(a). Eli Lilly announced the peer-reviewed results of its Phase 2 trial of lepodisiran on Sunday, which involved over 300 people genetically predisposed to high Lp(a). People taking the hi
Keywords: drug given lepodisiran lp people
Find related items on AmazonGo K’awiil is a project by nerdhub.co that curates technology news from a variety of trusted sources. We built this site because, although news aggregation is incredibly useful, many platforms are cluttered with intrusive ads and heavy JavaScript that can make mobile browsing a hassle. By hand-selecting our favorite tech news outlets, we’ve created a cleaner, more mobile-friendly experience.
Your privacy is important to us. Go K’awiil does not use analytics tools such as Facebook Pixel or Google Analytics. The only tracking occurs through affiliate links to amazon.com, which are tagged with our Amazon affiliate code, helping us earn a small commission.
We are not currently offering ad space. However, if you’re interested in advertising with us, please get in touch at [email protected] and we’ll be happy to review your submission.